论文部分内容阅读
目的观察白三烯受体拮抗剂孟鲁司特(顺尔宁)对重症支气管哮喘的临床疗效。方法选择本院重症住院患者68例,随机分成实验组36例,在常规静脉使用甲泼尼龙、氨茶碱基础上,加用顺尔宁,如有急性呼吸道感染(ARI)合并细菌感染时,加用抗生素治疗。对照组32例,除不用顺尔宁治疗外,其余治疗均与治疗组相同。结果治疗后两组患者的临床症状及动脉血气(PaO2和PaCO2)和临床症状较治疗前均有显著改善,而且治疗组与对照组比较差异有统计学意义。结论白三烯受体拮抗剂孟鲁司特(顺尔宁)对重症支气管哮喘治疗效果明显。
Objective To observe the clinical efficacy of montelukast (SD), a leukotriene receptor antagonist, on severe bronchial asthma. Methods Sixty-eight patients in our hospital were randomly divided into experimental group (36 cases) and routine intravenous methylprednisolone and aminophylline plus cis-ningling. In the case of acute respiratory infection (ARI) complicated with bacterial infection, Plus antibiotic treatment. Control group of 32 cases, except without treatment with cis-ning, the remaining treatment were the same as the treatment group. Results After treatment, the clinical symptoms, arterial blood gas (PaO 2 and PaCO 2) and clinical symptoms in both groups were significantly improved compared with those before treatment, and the difference between the treatment group and the control group was statistically significant. Conclusion Leukotriene receptor antagonist montelukast (SD) is effective in treating severe bronchial asthma.